Ilia I. Ouspenski

Array ( [id] => 13957947 [patent_doc_number] => 20190055317 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => TREATMENT WITH ANTI-ErbB2 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/173216 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24332 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16173216 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685097 [patent_doc_number] => 20190241663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => Anti-B7-H4 Antibodies and Immunoconjugates [patent_app_type] => utility [patent_app_number] => 16/167000 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16167000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16735673 [patent_doc_number] => 10961309 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-03-30 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS [patent_app_type] => utility [patent_app_number] => 16/167226 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 68 [patent_no_of_words] => 22989 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16167226 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15132773 [patent_doc_number] => 10479833 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-19 [patent_title] => Anti-CTLA-4 antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/165833 [patent_app_country] => US [patent_app_date] => 2018-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 61 [patent_no_of_words] => 41635 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16165833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14182751 [patent_doc_number] => 20190111080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS [patent_app_type] => utility [patent_app_number] => 16/163233 [patent_app_country] => US [patent_app_date] => 2018-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16163233 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986575 [patent_doc_number] => 20190062445 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => FULLY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB [patent_app_type] => utility [patent_app_number] => 16/136876 [patent_app_country] => US [patent_app_date] => 2018-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10755 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16136876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733263 [patent_doc_number] => 20180371099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/115343 [patent_app_country] => US [patent_app_date] => 2018-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16115343 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982587 [patent_doc_number] => 20190060451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => ANTIGEN BINDING PROTEINS THAT BIND PD-L1 [patent_app_type] => utility [patent_app_number] => 16/111995 [patent_app_country] => US [patent_app_date] => 2018-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111995 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072385 [patent_doc_number] => 20190085080 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => B7-H4 ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/111064 [patent_app_country] => US [patent_app_date] => 2018-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44168 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -46 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16111064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16198649 [patent_doc_number] => 10723799 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-28 [patent_title] => Anti-PD-L1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/100065 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23985 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 95 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100065 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13944721 [patent_doc_number] => 10208119 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Anti-PD-L1 antibodies and uses thereof [patent_app_type] => utility [patent_app_number] => 16/100019 [patent_app_country] => US [patent_app_date] => 2018-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23924 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16100019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16808222 [patent_doc_number] => 20210130775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => CELLS EXPRESSING A CHIMERIC ANTIGEN RECEPTOR OR ENGINEERED TCR AND COMPRISING A NUCLEOTIDE SEQUENCE WHICH IS SELECTIVELY EXPRESSED [patent_app_type] => utility [patent_app_number] => 16/635740 [patent_app_country] => US [patent_app_date] => 2018-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14722 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16635740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18965260 [patent_doc_number] => 11899017 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-13 [patent_title] => Predictive peripheral blood biomarker for checkpoint inhibitors [patent_app_type] => utility [patent_app_number] => 16/634833 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 25 [patent_no_of_words] => 22772 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16634833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929135 [patent_doc_number] => 20190048083 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => REGULATORY T CELL MEDIATOR PROTEINS AND USES THEROF [patent_app_type] => utility [patent_app_number] => 16/046660 [patent_app_country] => US [patent_app_date] => 2018-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45895 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16046660 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963193 [patent_doc_number] => 20200165348 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => CD123-BINDING CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 16/632086 [patent_app_country] => US [patent_app_date] => 2018-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34192 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16632086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19339462 [patent_doc_number] => 12049643 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-30 [patent_title] => Methods and compositions for modulating cytotoxic lymphocyte activity [patent_app_type] => utility [patent_app_number] => 16/630887 [patent_app_country] => US [patent_app_date] => 2018-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 74 [patent_figures_cnt] => 134 [patent_no_of_words] => 109796 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16630887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18575529 [patent_doc_number] => 11732043 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Antibodies that modulate a biological activity expressed by a cell [patent_app_type] => utility [patent_app_number] => 16/628939 [patent_app_country] => US [patent_app_date] => 2018-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 40 [patent_no_of_words] => 26719 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16628939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14390889 [patent_doc_number] => 10308714 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-04 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/024340 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39903 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024340 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14422603 [patent_doc_number] => 10316091 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-06-11 [patent_title] => Cancer immunotherapy by disrupting PD-1/PD-L1 signaling [patent_app_type] => utility [patent_app_number] => 16/024333 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 39863 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16024333 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16275604 [patent_doc_number] => 10758611 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-01 [patent_title] => Vector co-expressing vaccine and costimulatory molecules [patent_app_type] => utility [patent_app_number] => 16/016771 [patent_app_country] => US [patent_app_date] => 2018-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 49 [patent_no_of_words] => 24853 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16016771 [rel_patent_id] =>[rel_patent_doc_number] =>)